<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="406">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951834</url>
  </required_header>
  <id_info>
    <org_study_id>SUN-AK</org_study_id>
    <nct_id>NCT00951834</nct_id>
  </id_info>
  <brief_title>Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease</brief_title>
  <acronym>SUN-AK</acronym>
  <official_title>Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EGCG has shown a neuroprotective effect in cell-experimental and animal studies. The&#xD;
      neuroprotective mechanism of EGCG probably bases - besides the known antioxidant effect -&#xD;
      amongst others on the modulation of several signal transduction pathways, the influence on&#xD;
      the expression of genes which regulate cell survival resp. programmed cell death, as well as&#xD;
      the modulation of the mitochondrial function. In different Alzheimer models EGCG seems to&#xD;
      cause an induction of alpha-secretase and the endothelin-converting-enzyme, as well as to&#xD;
      prevent the aggregation of beta-amyloid to toxic oligomers through the direct binding to the&#xD;
      unfolded peptide.&#xD;
&#xD;
      The investigators therefore expect EGCG to have a positive influence on the course of the&#xD;
      Alzheimer´s Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is a progressive dementia characterised by an ongoing loss of memory&#xD;
      function and of at least one additional cognitive domain resulting in impairment of daily&#xD;
      life functioning. Treatment of diseases such as diabetes mellitus, fractures and&#xD;
      cardiovascular diseases is more expensive and complicated in patients with dementia compared&#xD;
      to those without. The yearly costs for treatment and care of AD patients in the US are&#xD;
      estimated to exceed 100 billion USD. Life expectancy is reported to be about 10 years after&#xD;
      establishment of the diagnosis and is significantly reduced compared to non-demented subjects&#xD;
      of similar age and socio-economic status.&#xD;
&#xD;
      Age is the most relevant risk factor for AD, followed by genetic factors. Prevalence is less&#xD;
      than 1% amongst individuals aged 50-60, but is reported to double every 5 years beyond the&#xD;
      age of 60. The prevalence exceeds 30% in the age of 85-90.&#xD;
&#xD;
      The only standard therapy for AD are acetylcholine-esterase inhibitors (AchEI; donepezil,&#xD;
      galantamine, rivastigmine). AchEI exhibit a temporary stabilizing mild effect on the&#xD;
      progression of AD. Conversion rates from &quot;mild cognitive impairment&quot; to AD do not seem to be&#xD;
      beneficially influenced by AchEI. A high percentage of premature study withdrawals owing to&#xD;
      adverse events has been observed in AchEI studies published to date. The questionable benefit&#xD;
      may further be outweighed by high costs of the AchEI.&#xD;
&#xD;
      Therefore, there is a necessity for the development of more efficacious and less expensive&#xD;
      disease-modifying drugs with a better safety and tolerability profile. EGCG is a promising&#xD;
      compound which has proven efficacious in AD animal models and which has shown an excellent&#xD;
      tolerability in our 18-month clinical trial on Multiple Sclerosis currently being performed&#xD;
      at our institution (SuniMS study, NCT00525668).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-COG (Score 0-70) (Baseline to treatment)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the verum</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE (Score 0-30) after 18 months compared to baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospitalisation and Time to death related to AD</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy assessed by brain MRI</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-ADAS-COG and Baseline-MMSE as covariates</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC+ and WHO-QOL-Bref</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test and MVGT</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Epigallocatechin-Gallate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Months 1-3: 200 mg EGCG/die (200-0-0 mg)&#xD;
Months 4-6: 400 mg EGCG/die (200-0-200 mg)&#xD;
Months 7-9: 600 mg EGCG/die (400-0-200 mg)&#xD;
Months 10-18: 800 mg EGCG/die (400-0-400 mg)&#xD;
add-on to Donepezil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>add-on to Donepezil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epigallocatechin-Gallate</intervention_name>
    <description>Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:&#xD;
Months 1-3: 200 mg EGCG/die (200-0-0 mg)&#xD;
Months 4-6: 400 mg EGCG/die (200-0-200 mg)&#xD;
Months 7-9: 600 mg EGCG/die (400-0-200 mg)&#xD;
Months 10-18: 800 mg EGCG/die (400-0-400 mg)</description>
    <arm_group_label>Epigallocatechin-Gallate</arm_group_label>
    <other_name>Sunphenon EGCG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  early stage of AD (Diagnosis DSM-IV and NINCDS/ADRDA, Dubois-criteria 2007)&#xD;
&#xD;
          -  age 60-100&#xD;
&#xD;
          -  MMSE 20-26&#xD;
&#xD;
          -  patient lives at home with at least one relative who perform external&#xD;
             ratings/assessment&#xD;
&#xD;
          -  co-medication with Donepezil (Aricept®, Pfizer Pharma GmbH) with at least 3 months to&#xD;
             maximum 6 months of existing stable medication&#xD;
&#xD;
          -  maximum of 2 cups of black tea/die, no green tea, not more than &gt; 500 ml/die of&#xD;
             grapefruit juice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  co-medication with NSAIDs (longterm medication) (ASS is not an exclusion criteria),&#xD;
             Gingko- or other natural extracts, other anti-dementiva except of Donepezil&#xD;
&#xD;
          -  familial autosomal-dominant inherited AD&#xD;
&#xD;
          -  instable medical condition&#xD;
&#xD;
          -  other primary psychiatric/neurologic disorders&#xD;
&#xD;
          -  missing informed consent&#xD;
&#xD;
          -  no readiness to save and refer pseudonym personal data&#xD;
&#xD;
          -  hospitalisation due to juridical or legal regulation&#xD;
&#xD;
          -  any condition disturbing or making MRI and other measures impossible&#xD;
&#xD;
          -  clinically relevant GI-disorders at screening and 1 year before&#xD;
&#xD;
          -  clinically relevant lung, infectious, heart or other CNS disorders, clinical or&#xD;
             paraclinical suspicion of TBC, history of vascular CNS-disorders at screening and 1&#xD;
             year before&#xD;
&#xD;
          -  clinically relevant liver disorders at screening and 1 year before&#xD;
&#xD;
          -  clinically relevant functional disorders of liver, kidney or bone marrow defined by&#xD;
             following lab values at screening:&#xD;
&#xD;
               -  Marrow dysfunction:&#xD;
&#xD;
                    -  HB &lt; 8,5 g/dl&#xD;
&#xD;
                    -  WBC &lt; 2,5/nl&#xD;
&#xD;
                    -  Thrombocytes &lt; 125/nl&#xD;
&#xD;
               -  Kidney dysfunction:&#xD;
&#xD;
                    -  Creatinin-Clearance according to Cockcroft-Gault-Formula: Cl &lt; 110ml/min&#xD;
                       (male) resp. Cl &lt; 95ml/min (female), from the age of 30 decline of 10ml/min&#xD;
                       per decade&#xD;
&#xD;
               -  Liver dysfunction:&#xD;
&#xD;
                    -  ASAT/ALAT &gt; 3.5 x higher than the upper reference value&#xD;
&#xD;
                    -  Bilirubin &gt; 2.0 mg/dl&#xD;
&#xD;
          -  known allergy of elements of Sunphenon EGCg or additives of Sunphenon EGCg resp.&#xD;
             placebo&#xD;
&#xD;
          -  long-term hepatotoxic medication&#xD;
&#xD;
          -  current intake of cytochrom P450 3A4-inhibitors or -inductors, such as antimycotics of&#xD;
             the azol-type or macrolide-antibiotics&#xD;
&#xD;
          -  clinical-anamnestic or paraclinical manifestations suggesting an alcohol or drug abuse&#xD;
&#xD;
          -  participation in any clinical trial &lt; 3 months prior to screening or ongoing&#xD;
&#xD;
          -  any medical, psychiatric or other condition which might constrain the ability of the&#xD;
             patient to understand the informed consent, to give consent, to adhere to the protocol&#xD;
             or to accomplish the study&#xD;
&#xD;
          -  massive and extended sun exposure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Medicine Berlin, NeuroCure</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neurocure.de</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Alzheimer´s Disease</keyword>
  <keyword>Epigallocatechin-Gallate</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>ADAS-COG</keyword>
  <keyword>early stage of Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

